Methods: Cost-Effectiveness Analyses
Scan featured sets of analyses by topic below.
This analysis used decision analytic modeling to estimate the health impact, financial costs, and cost-effectiveness (dollars per disability-adjusted years of life averted) of scaling-up coverage of two-dose HPV vaccination of 10 year old girls, and once per lifetime cervical cancer screening of women at age 35, in 50 low- and lower-middle-income countries. Learn more.
Cost-effectiveness acceptability curves summarize the distribution of expected benefits and costs in the context of multivariate uncertainty, but don't distinguish between joint distributions of costs and effects that are correlated but differ in scale. Learn how cost-effectiveness and affordability were both considered for HBV vaccination in the Gambia.
In global health, interventions that impose costs per disability-adjusted life year averted less than three and one times GDP per capita are often considered cost-effective and very cost-effective, respectively. This article explores the conceptual foundation and derivation of these thresholds, and suggests options for improvement. Learn more.
Cost-Effectiveness Methods 2
Publications, Papers and Briefs: Cost-Effectiveness Thresholds
Dakin H, Devlin N, Feng Y et al. 2014. The influence of cost-effectiveness and other factors on NICE decisions. Health Economics. 24;(10):1256–1271.</p>
<p>Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford: Oxford: Oxford University Press, 2015.</p>
<p>Marseille E, Larson B, Kazi D, Kahn J, Rosen S. WHO Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull. World Health Organisation 2015;93:118–124.</p>
<p>McCabe C, Claxton K, Culyer A. The NICE cost-effectiveness threshold – What it is and what that means. Pharmacoeconomics. 2008;26(9):733-744.</p>
<p>Newall A, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics 2014;32: 525–31.</p>
<p><strong>Neumann P,</strong> Cohen J, <strong>Weinstein M</strong>. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. The New England Journal of Medicine 2014;371(9):796–7.</p>
<p>Nimdet K, Ngorsuraches S. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand. BMJ Open 2015;5(10):p.e008123.</p>
<p>Ochalek J, Lomas J, Claxton K. Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data. York, UK: Centre for Health Economics, University of York. 2015 Dec, p. 1-50. (CHE Research Paper;122).</p>
<p>Revill P, Walker S, Madan J, Ciaranello A, Mwase T, Gibb D, Claxton K, Sculpher M. Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: are current international norms fit for purpose? Centre for Health Economics, University of York. 2014 May, p. 1-15 (CHE Research Paper;98).</p>
<p><strong>Robinson L, Hammitt J, Chang A, Resch S</strong>. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Planning. doi: 10.1093/heapol/czw096 First published online: July 24, 2016.</p>
<p>Ryen L, Svensson M. The willingness to pay for a quality adjusted life year: a review of the empirical literature. Health Economics 2015; 24(10): 1289–1301.</p>
<p>Vallejo-Torres L, García-Lorenzo B, Castilla I, Valcárcel-Nazco C, Lidia García-Pérez L, et al. On the estimation of the cost-effectiveness threshold: Why, what, how? Value in Heath. First published online: 23 April, 2016.</p>
<p>Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value in Health 2016;Feb 20.</p>